Shailender Bhatia

Summary

Publications

  1. ncbi Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
    Shailender Bhatia
    Medical Oncology, University of Washington, Seattle, WA, USA
    PLoS ONE 7:e48787. 2012
  2. ncbi Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer
    Shailender Bhatia
    Departments of Medicine Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 98109, USA
    Curr Oncol Rep 13:488-97. 2011
  3. ncbi Treatment of metastatic melanoma: an overview
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    Oncology (Williston Park) 23:488-96. 2009
  4. ncbi Systemic therapy for metastatic melanoma in 2012: dawn of a new era
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
    J Natl Compr Canc Netw 10:403-12. 2012
  5. ncbi Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 109:4592-7. 2012
  6. ncbi Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report
    Shailender Bhatia
    Department of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    J Immunother 32:203-5. 2009
  7. ncbi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008
  8. ncbi Temsirolimus in patients with advanced renal cell carcinoma: an overview
    Shailender Bhatia
    Division of Medical Oncology, Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Adv Ther 26:55-67. 2009
  9. ncbi Emerging and mechanism-based therapies for recurrent or metastatic merkel cell carcinoma
    Natalie J Miller
    Departments of Medicine Dermatology, Pathology, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA
    Curr Treat Options Oncol 14:249-63. 2013

Collaborators

Detail Information

Publications9

  1. ncbi Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
    Shailender Bhatia
    Medical Oncology, University of Washington, Seattle, WA, USA
    PLoS ONE 7:e48787. 2012
    ..This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with carboplatin and paclitaxel (CP) in metastatic uveal melanoma...
  2. ncbi Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer
    Shailender Bhatia
    Departments of Medicine Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 98109, USA
    Curr Oncol Rep 13:488-97. 2011
    ..Here we review recent discoveries in MCC with a special focus on the pathogenic role of Merkel cell polyomavirus and the immunobiology of this virus-associated disease...
  3. ncbi Treatment of metastatic melanoma: an overview
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    Oncology (Williston Park) 23:488-96. 2009
    ..In this article, we review the treatments for metastatic melanoma including promising investigational approaches...
  4. ncbi Systemic therapy for metastatic melanoma in 2012: dawn of a new era
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
    J Natl Compr Canc Netw 10:403-12. 2012
    ..This article reviews both the current systemic treatment options for metastatic melanoma and promising investigational approaches...
  5. ncbi Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 109:4592-7. 2012
    ....
  6. ncbi Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report
    Shailender Bhatia
    Department of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    J Immunother 32:203-5. 2009
    ..We discuss the pathophysiology and suggest careful monitoring of patients for development of this complication from ipilimumab therapy...
  7. ncbi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008
    ....
  8. ncbi Temsirolimus in patients with advanced renal cell carcinoma: an overview
    Shailender Bhatia
    Division of Medical Oncology, Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Adv Ther 26:55-67. 2009
    ..The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed...
  9. ncbi Emerging and mechanism-based therapies for recurrent or metastatic merkel cell carcinoma
    Natalie J Miller
    Departments of Medicine Dermatology, Pathology, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA
    Curr Treat Options Oncol 14:249-63. 2013
    ..Due to their encouraging efficacy, low toxicity, and lack of immune suppression, these therapies may offer viable alternatives to traditional cytotoxic chemotherapy...